Amyris Inc (NASDAQ: AMRS)
Amyris has had an incredible run in the market as of late, and for good reason. The company has been awarded contract after contract that will likely lead to strong revenue in the long run. Today, yet another reason to be bullish has surfaced. Early this morning, the company announced that a product using its biotechnology has launched. Today, we’ll talk about the launch, how the stock is reacting to the news, and what we can expect to see from AMRS moving forward. So, let’s get right to it…
Trade smarter and make more money with Tradespoon!
AMRS Announces Launch Of The Illuminator
As mentioned above, Amyris is a strong company that has announced yet another reason to be bullish. Recently, the company has worked with Biossance, a pioneer in sustainable beauty. The two companies have been working on a product that was launched today. That product is known as The Illuminator.
The Illuminator is a dual peptide, weightless eyelid gel that has achieved exceptional clinical results. The gel is a nontoxic product that takes advantage of weightless hydrating. The product combines the benefits of squalane, a 100% plant-derived product produced by AMRS, with dual peptides. As a result of this combination, dark circles and puffiness are reduced. Also, cell extract from Swiss apples helps to rejuvenate the delicate skin in and around the eye area. In fact, A-list celebrity makeup artist Katey Denno has already said that she was impressed with the product. Here’s what she had to say:
“The Illuminator is a fantastic, natural solution designed specifically for the delicate eye area to keep you looking fresh and radiant. It’s essential to have such an innovative product that’s free from harmful ingredients…”
The above statement was followed up by Caroline Hadfield, SVP of Personal Care at AMRS. Here’s what she had to say:
“The innovative Biossance skincare line, continues to deliver strong sales growth by delivering on consumer demand for natural, high performing products. Just as in food products, today’s educated consumer is increasingly interested in knowing that their skincare products are not detrimental to them, their families, or their planet…”
How The Stock Reacted To The News
While the news released with regard to Amyris was overwhelmingly positive, recent macro-economic news is weighing heavily on the market today. Unfortunately, this weight is leading to declines on AMRS in spite of the positive news that was released today. Currently (11:07), the stock is trading at $0.43 per share after a loss of $0.01 per share (2.86%) thus far today.
What We Can Expect To See Moving Forward
Moving forward, I have an overwhelmingly bullish opinion of what we can expect to see from AMRS. While news with regard to the FOMC meeting minutes is weighing heavily on the market today, I’m not concerned. The launch of the new product will likely lead to strong growth in revenue at Amyris. However, my bullish opinion goes far beyond this product. As mentioned above, the company has been the subject of several recent contracts, all with the potential to advance revenue and earnings in a big way in the long run. All in all, I’m expecting to see gains in the stock ahead.
Don’t waste your time! Click here to find winning trades in minutes!
What Do You Think?
Where do you think AMRS is headed moving forward? Join the discussion at TalkTRENDZ!
[Image Courtesy of Wikimedia]